Stanford Antimicrobial Safety & Sustainability Program. Stanford University School of Medicine, Division of Infectious Diseases 🦠 | BCIDP | He/Him/His
San Francisco, CA
Joined October 2018
- Tweets710
- Following210
- Followers437
- Likes3.4K
Pinned Tweet
Limiting the duration of antibiotic therapy is an attractive stewardship intervention with the potential to improve patient outcomes. However, applying this intervention to the SOT population is complicated by prevailing prescribing cultures and lack of data. #IDtwitter
Thank you @Stanford_ID for this recognition.. Can’t wait to see all the amazing things you’ll do!
Will A retweeted
Creative combination treatment ideas for this isolate? CF patient s/p lung transplant in 2022. @Willeeuhmm @DHpharmd @jfsisaacs5
Will A retweeted
👋 @Willeeuhmm! Not sure if our peds experience is of interest but our center recs cefazolin x 24 hr post-kidney transplant regardless of deceased or living donor. Donor or recipient cultures preceding may be taken into consideration. Looking forward to hearing other responses!
Question for #TxID #IDTwitter
Does your center provide different abx surg ppx recs for kidneys coming from deceased vs living donors? Ex pip tazo for deceased vs cefazolin for living. Also, any difference in duration of abx ppx (eg 48 vs <24 hrs) @TransplantIDNet @StanfordASP
Will A retweeted
Next up is Dr. Will Allegria to talk about stewardship in Immunocompromised patients.
This is a complicated patient population.
#SHEASpring2024
1/
Congrats, Alex (@AlexZimmet), David (@DHpharmd), Emily (@EmilyMui), Mary Smith, Marty (@MartenHawkins), Will (@Willeeuhmm), and Marisa (@Marisa_Holubar)!
More excellent work from our awesome stewardship department headed up by Dr. Marisa Holubar!
Will A retweeted
Congrats, Alex (@AlexZimmet), David (@DHpharmd), Emily (@EmilyMui), Mary Smith, Marty (@MartenHawkins), Will (@Willeeuhmm), and Marisa (@Marisa_Holubar)!
More excellent work from our awesome stewardship department headed up by Dr. Marisa Holubar!
“Electronic Phenotyping” Antimicrobials to Facilitate Outpatient Stewardship for Asymptomatic Bacteriuria and Urinary Tract Infection in Renal Transplant
✍️ @AlexZimmet, @DHpharmd, @MartenHawkins, @Willeeuhmm, @Marisa_Holubar, @Stanford_ID
🔗 bit.ly/3VibOAU
Will A retweeted
Combination Antifungal Therapy for Invasive Mucormycosis in Immunocompromised Hosts: A Single-Center Experience
✅ Just Accepted
🔓 Open Access
🔗 bit.ly/3OTb8OF
@DHpharmd @jessicawithID @Pharm_Bean @EmilyMui @StanDeresinski @Marisa_Holubar @Willeeuhmm
Will A retweeted
🆕️🔥 Single centre cohort study @StanfordASP @bluPharmD @DHpharmd &🌟s*
In immunocompromised pts with Invasive Mucormycosis neither upfront nor salvage antifungal combo Rx was associated with a difference in 6 week mortality compared to monotherapy
academic.oup.com/ofid/advanc…
Great session with 🌟panelists. Great to see two of my personal mentors on stage @Marisa_Holubar @Payal_Patel who have helped shape my own career! @IDSAInfo @SIDPharm #IDWeek2023
Will A retweeted
Nagel Pharmily Reunion @IDWeekmtg! (Missing Marie, Twisha, Farnaz, @Willeeuhmm @NikkiTranID) #IDWeek2023 @MMAbxStew – at Boston, MA
Bummed we couldn’t get a group pic with everyone but it was great strategic planning day @StanfordASP – at Palo Alto, CA
“Race and ethnicity were determined by clinicians and were not self-reported”
-Paper published in JAMA
Genuinely curious how a clinician would make that determination 🤷🏽♂️
2
1
692
Will A retweeted
Proud of Brian Lu (@bluPharmD) our PGY2 ID resident on presenting his poster at #MADID2023 on invasive mucormycosis! @Willeeuhmm @Marisa_Holubar @StanDeresinski @jessicawithID @Pharm_Bean @EmilyMui
Will A retweeted
Invasive mucormycosis is an uncommon infix that has been associated with high rates of mortality. Differences in pt host factors, dx presentation, and mgmt practices have made it difficult to ascertain efficacy of interventions with invasive mucormycosis. @MAD_ID_ASP #MADID2023
Will A retweeted
So proud of our ⭐ brilliant ⭐ @Stanford_ID fellows @AlexZimmet @RalphTayyarMD and Krithi Srinivasan presenting research at #SHEASpring2023! Rock stars! 🤩
Will A retweeted
Isavuconazole is the only US FDA-approved antifungal for treating invasive mucormycosis
🆕️⚡️⚡️ #JOF
@mcastanheirajmi
Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific
mdpi.com/2309-608X/9/2/241
Will A retweeted
Had the privilege of representing @SIDPharm at the #IDWeek2023 planning committee meeting over the past two days which was a blast! Amazing teamwork by each of the committees and I can’t wait for everyone to experience all of the great content planned for Boston this fall!
I was today years old when I learned there was a pharmacist shortage in 🇺🇸 🙄
An apparent shortage of pharmacists is forcing CVS and Walmart to reduce the hours of its pharmacies, as they close earlier in thousands of locations. cnn.it/3HErhEc
241